Diabetic macular edema

Dis Mon. 2021 May;67(5):101138. doi: 10.1016/j.disamonth.2021.101138. Epub 2021 Feb 10.

Abstract

Diabetic retinopathy (DR) is a leading cause of preventable blindness world-wide. Diabetic macular edema (DME) is the most common cause of moderate vision loss in patients with diabetes. Although treatments for DME have improved significantly over the past decades, the burden of this disease remains high for patients and the healthcare system alike. The role of the primary care provider is critical in the prevention and prompt referral for management of DME.

Keywords: Anti-VEGF; Diabetic macular edema; Diabetic retinopathy; Fluorescein angiography; Optical coherence tomography.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Diabetes Complications / complications*
  • Humans
  • Intravitreal Injections
  • Low-Level Light Therapy
  • Macular Edema / diagnosis
  • Macular Edema / epidemiology
  • Macular Edema / etiology*
  • Macular Edema / therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vision Disorders / etiology

Substances

  • Adrenal Cortex Hormones
  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A